STATEMENT: Patients For Affordable Drugs Supports Alzheimer’s Association’s Denunciation Of Aduhelm’s Price Set By Biogen
"We stand with the Alzheimer’s Association in its denunciation of the price set by Biogen for the drug Aduhelm."
STATEMENT: Aducanumab FDA Approval And Biogen’s Pricing Prove Urgent Need For Medicare Negotiation
“Today, we are watching our drug pricing system break under the weight of Medicare’s inability to negotiate lower drug prices."
Patients For Affordable Drugs Releases New Video Debunking Big Pharma’s Myths About Innovation and Drug Prices
Patients For Affordable Drugs (P4AD) released a new video today debunking Big Pharma’s myth that any limits on its unilateral power to dictate prices on brand-name drugs will kill innovation and new drug development.
ICYMI: New York Times Opinion: Taxpayers Fund Research and Drug Companies Make a Fortune
The New York Times today published an op-ed by David Mitchell, cancer patient and founder of Patients For Affordable Drugs.
Patients For Affordable Drugs Announces New Communications Director
As The Fight To Lower Drug Prices Ramps Up, Audrey Baker Will Lead P4AD’s Communications Efforts
Big Pharma’s Big Lie: The Truth About Innovation and Drug Pricing
New Report Debunks Pharma's Claim That Any Restraint On Its Unilateral Pricing Power Will Destroy Innovation And Access To New Medicines.
Patients For Affordable Drugs Names Executive Director
Veteran Advocacy Leader Sheila McLean Takes The Helm At Critical Moment For Drug Pricing Reform.
Hoping We Wouldn’t Notice? Pharma Spreads Out Its New Year Price Hikes
Nearly 150 More Price Increases In Just The Last Two Weeks Bring Total To 783
